ERAS

Conviction 100HealthcareScan · Mon, Aug 10, 2026

Tweezer bottom

ERAS$18.10-1.68%

ResistanceSupportVol 14

Vol MA14 3.79M

May 11May 28Jun 16Jul 6Jul 23Aug 10

Erasca, Inc.PHARMACEUTICAL PREPARATIONSwww.erasca.com ↗

Price18.10

Change-1.68%

Gap-2.23%

Rel volume2.25×

Avg volume4.75M

Avg $ vol90.14M

SMA 2018.82

SMA 5016.78

SMA 20011.38

Price vs 50+7.88%

Price vs 200+59.04%

MA stackbullish

50/200 cross—

Supertrendup · 16.56

RSI (14)50

MACD hist-0.23

MACD cross—

Stoch %K / %D35 / 41

ADX (14)18

+DI / −DI19 / 18

RSI divergence—

MACD divergence—

ATR %+6.15%

ADR %6.15%

52w high22.47

52w low1.40

From 52w high-19.45%

Above 52w low+1192.86%

New 52w highNo

SqueezeOff

Bollinger width16.48%

%B0.27

Donchian pos22.57%

Donchian high21.60

Donchian low17.08

AVWAP (52w high)14.70

vs AVWAP high+23.10%

AVWAP (52w low)11.85

vs AVWAP low+52.68%

OBV trendFlat

Chaikin MF (20)0.03

Today vs 20d2.25×

Avg vol (14d)3.79M

Avg vol (20d)4.75M

Avg $ vol (20d)90.14M

Market cap—

RS 3m (vs SPY)+71.32%

RS 6m (vs SPY)+40.85%

RS line new highNo

Trend template8/8

Technical rank78.5

1 week+1.46%

1 month-2.32%

3 months+78.85%

6 months+47.27%

1 year+1139.73%

YTD+404.18%

P/E-45.94

P/B14.54

P/S—

P/FCF-59.87

EPS-0.4400

Div yield—

ROE-31.65%

ROA-27.00%

Debt/Eq—

Current9.52

EV/EBITDA-41.18

Gross margin—

Net margin—

Rev growth—

EPS growth22.95%

Price target22.22

Target upside20.76%

Analyst ratingBuy

Institutional85.23%

Ent. value5.67B

Revenue—

Net income-183.44M

Gross profit—

Free cash flow-95.58M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out310.98M

Employees103

ListedFri, Jul 16, 2021

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeA+

Conviction100 / 100

Pattern quality—

Tech rank78.5 / 100

Group rank86 / 100 · Leading

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmTweezer bottom

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ERAS

All disclosures →

No recent disclosed trades by Congress in ERAS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ERAS · 6 buys

Insider	Side	Shares	Value	Traded	Filed
Hambleton Julie Director · Stock option (right to buy) · 2026-06-26	Grant	29.89K	—	2026-06-26	2026-06-29
Bristol James Arthur Director · Stock option (right to buy) · 2026-06-26	Grant	29.89K	—	2026-06-26	2026-06-29
LIU JEAN I Director · Stock option (right to buy) · 2026-06-26	Grant	29.89K	—	2026-06-26	2026-06-29
Casdin Alexander W. Director · Stock option (right to buy) · 2026-06-26	Grant	29.89K	—	2026-06-26	2026-06-29
Multani Pratik S Director · Stock option (right to buy) · 2026-06-26	Grant	29.89K	—	2026-06-26	2026-06-29
Start Valerie Denise Harding Director · Stock option (right to buy) · 2026-06-26	Grant	29.89K	—	2026-06-26	2026-06-29

SEC filings

EDGAR filings in ERAS · 8 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.